Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer

Kou, Changhua; Zhou, Tian; Han, Xilin; Zhuang, Huijie; Qian, Haixin

doi:10.3892/ol.2016.5265

Cited by 43 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, although downregulation of plasma miR-23b was reported to be a potential diagnostic and prognostic biomarker in colorectal cancer 40 , the association between miR-23 and mental disorders remains unknown. Recently, miR-23b was noted to be downregulated during encephalomyelitis and may have an anti-inflammatory role in central nervous system inflammation 41 .…”

Section: Discussionmentioning

confidence: 99%

Serum miRNA as a possible biomarker in the diagnosis of bipolar II disorder

Lee

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The diagnosis of Bipolar II disorder (BD-II) is currently based on the patients' description of symptoms and clinical behavioral observations. This study explored the possibility of miRNA in peripheral blood (serum) as a specific biomarker for BD-II. We identified 6 candidate miRNAs to differentiate BD-II patients from controls using next-generation sequencing. We then examined these candidate miRNAs using real-time PCR in the first cohort (as training group) of 79 BD-II and 95 controls. A diagnostic model was built based on these candidate miRNAs and then tested on an individual testing group (BD-II: n = 20, controls: n = 20). We found that serum expression levels of miR-7-5p, miR-23b-3p, miR-142-3p, miR-221-5p, and miR-370-3p significantly increased in BD-II compared with controls in the first cohort, whereas that of miR-145-5p showed no significant difference. The diagnostic power of the identified miRNAs was further analyzed using receiver-operating characteristic (ROC). Support vector machine (SVM) measurements revealed that a combination of the significant miRNAs reached good diagnostic accuracy (AUC: 0.907). We further examined an independent testing group and the diagnostic power reached fair for BD-II (specificity = 90%, sensitivity = 85%). We constructed miRNA panels using SVM model, which may aid in the diagnosis for BD-II.Bipolar disorder (BD) has several subtypes. Bipolar I disorder (BD-I) and bipolar II disorder (BD-II) are two of the most commonly seen subtypes of BD. BD-I and BD-II differ in clinical presentation: BD-I involves one or more manic or mixed episodes in addition to one or more major depressive episodes. BD-II is characterised by at least one hypomanic episode with one or more major depressive episodes 1,2 . BD-II has become the focus of increasing attention and has been recognised as a unique disorder. Its prevalence rate ranges from 3% to 11% 3 . Nevertheless, because of the complex spectrum of symptoms, the diagnosis of BD remains subjective. Diagnosing BD is challenging because patients typically regard hypomanic episodes as a positive mood status or experience, and they only seek medical help during depressive episodes 4 . BD is initially misdiagnosed at a rate of approximately 40% and typically requires approximately 5-12 years to be correctly diagnosed and treated appropriately 5,6 . Delayed diagnosis and inefficacious treatment of BD-II may lead to a prolonged course, more affective episodes, and an increased suicide rate, adding further to its socioeconomic burden 5,7 .Accumulating evidence reveals that microribonucleic acids (miRNAs) are involved in many biological processes such as neurogenesis, neuroproliferation, and synaptic plasticity in the central nervous system 8,9 . Different expressions of peripheral miRNA have been reported in several mental disorders including schizophrenia, major depressive disorder, and Alzheimer disease [10][11][12] . Changes in peripheral miRNA may be correlated with changes in neuroendocrine or neuroimmune responses 13 . Because brain tissue ...

show abstract

Section: Discussionmentioning

confidence: 99%

Serum miRNA as a possible biomarker in the diagnosis of bipolar II disorder

Lee

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…2 Early disease detection and differentiation of GI cancer from other GI diseases could have a tremendous impact on both treatment strategies and prognosis. In people, plasma microRNA (miRNA) profiles have been investigated in colorectal cancer, both as diagnostic 3,4 and prognostic biomarkers 4,5 with encouraging results. Recently, noninvasive fecal miRNA profiles have been investigated in human patients with colorectal cancer showing promising results.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of microRNA stability in feces from healthy dogs

Cirera

Willumsen

Johansen

et al. 2018

Veterinary Clinical Pathol

View full text Add to dashboard Cite

Overall, miRNAs are present in dog feces at measurable levels. Some miRNAs seem to be subject to a higher degree of degradation in samples stored at room temperature for 24 hours compared with samples frozen after collection at -20°C. The investigated miRNAs were stably expressed over time. This study provides the basis for further research on miRNA expression profiles as biomarkers for gastrointestinal cancer in dogs.

show abstract

“…DNA hypermethylation is considered a commonsense factor in colorectal cancer and believed to have a bad prognosis with colorectal cancer by causing chromosomal instability and global imprinting loss . Specifically, many genes have been reported to be hypermethylated in colorectal cancer, such as KLOTHO, CDH13, NDRG2, SPRY4, CDX2, and mir‐23b etc. These genes usually have their promoter region methylated and down‐regulated in colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%